$44.46
00.00%
Pre-Market: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Ultragenyx Pharmaceutical
RARENASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock, Analyst Ratings, Price Targets, Forecasts
Ultragenyx Pharmaceutical Inc has a consensus price target of $92.77 based on the ratings of 26 analysts. The high is $141 issued by Barclays on August 3, 2021. The low is $45 issued by Wedbush on July 18, 2024. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Wedbush, and Cantor Fitzgerald on July 22, 2024, July 18, 2024, and June 12, 2024, respectively. With an average price target of $91.67 between Cantor Fitzgerald, Wedbush, and Cantor Fitzgerald, there's an implied 106.18% upside for Ultragenyx Pharmaceutical Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Wedbush
Goldman Sachs
B of A Securities
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for Ultragenyx Pharmaceutical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/22/2024 | Buy Now | 158.66% | Cantor Fitzgerald | Kristen Kluska | $115 → $115 | Reiterates | Overweight → Overweight | Get Alert |
| 07/18/2024 | Buy Now | 1.21% | Wedbush | Laura Chico | $45 → $45 | Reiterates | Neutral → Neutral | Get Alert |
| 06/12/2024 | Buy Now | 158.66% | Cantor Fitzgerald | Kristen Kluska | $115 → $115 | Reiterates | Overweight → Overweight | Get Alert |
| 06/06/2024 | Buy Now | 50.7% | Goldman Sachs | Salveen Richter | $56 → $67 | Upgrade | Neutral → Buy | Get Alert |
| 05/31/2024 | Buy Now | 7.96% | Wedbush | Laura Chico | $47 → $48 | Maintains | Neutral | Get Alert |
| 05/31/2024 | Buy Now | 70.94% | B of A Securities | Tazeen Ahmad | $83 → $76 | Maintains | Buy | Get Alert |
| 05/31/2024 | Buy Now | 149.66% | Canaccord Genuity | Whitney Ijem | $109 → $111 | Maintains | Buy | Get Alert |
| 05/31/2024 | Buy Now | 158.66% | Cantor Fitzgerald | Kristen Kluska | $107 → $115 | Maintains | Overweight | Get Alert |
| 05/31/2024 | Buy Now | 185.65% | Stifel | Dae Gon Ha | $124 → $127 | Maintains | Buy | Get Alert |
| 05/31/2024 | Buy Now | 61.94% | Baird | Joel Beatty | $68 → $72 | Maintains | Outperform | Get Alert |
| 05/06/2024 | Buy Now | 145.16% | Canaccord Genuity | Whitney Ijem | $111 → $109 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | 140.67% | Cantor Fitzgerald | Kristen Kluska | → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 05/03/2024 | Buy Now | 5.71% | Wedbush | Laura Chico | $48 → $47 | Maintains | Neutral | Get Alert |
| 04/24/2024 | Buy Now | 37.2% | TD Cowen | Yaron Werber | $59 → $61 | Maintains | Buy | Get Alert |
| 04/22/2024 | Buy Now | 73.19% | RBC Capital | Luca Issi | → $77 | Initiates | → Outperform | Get Alert |
| 04/17/2024 | Buy Now | 7.96% | Wedbush | Laura Chico | → $48 | Reiterates | Neutral → Neutral | Get Alert |
| 04/16/2024 | Buy Now | 7.96% | Wedbush | Laura Chico | → $48 | Reiterates | Neutral → Neutral | Get Alert |
| 04/05/2024 | Buy Now | 140.67% | Cantor Fitzgerald | Kristen Kluska | → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 03/18/2024 | Buy Now | 106.93% | JP Morgan | Anupam Rama | $88 → $92 | Maintains | Overweight | Get Alert |
| 02/27/2024 | Buy Now | 97.93% | JP Morgan | Cory Kasimov | $84 → $88 | Maintains | Overweight | Get Alert |
| 02/27/2024 | Buy Now | 140.67% | Cantor Fitzgerald | Kristen Kluska | → $107 | Maintains | Overweight | Get Alert |
| 02/21/2024 | Buy Now | 149.66% | Canaccord Genuity | Whitney Ijem | $110 → $111 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 7.96% | Wedbush | Laura Chico | $47 → $48 | Maintains | Neutral | Get Alert |
| 02/15/2024 | Buy Now | 156.41% | Cantor Fitzgerald | Kristen Kluska | → $114 | Reiterates | Overweight → Overweight | Get Alert |
| 01/30/2024 | Buy Now | 52.95% | Baird | Joel Beatty | $57 → $68 | Maintains | Outperform | Get Alert |
| 01/19/2024 | Buy Now | 156.41% | Cantor Fitzgerald | Kristen Kluska | → $114 | Reiterates | Overweight → Overweight | Get Alert |
| 12/08/2023 | Buy Now | 61.94% | Wells Fargo | Tiago Fauth | → $72 | Initiates | → Overweight | Get Alert |
| 11/03/2023 | Buy Now | 88.93% | Morgan Stanley | Jeffrey Hung | $90 → $84 | Maintains | Overweight | Get Alert |
| 10/25/2023 | Buy Now | 192.4% | Piper Sandler | Christopher Raymond | $135 → $130 | Maintains | Overweight | Get Alert |
| 10/10/2023 | Buy Now | 102.43% | Morgan Stanley | Jeffrey Hung | $95 → $90 | Maintains | Overweight | Get Alert |
| 09/25/2023 | Buy Now | 156.41% | Cantor Fitzgerald | Kristen Kluska | → $114 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | Buy Now | 113.68% | Morgan Stanley | Jeffrey Hung | $95 → $95 | Reiterates | Overweight → Overweight | Get Alert |
| 08/01/2023 | Buy Now | 84.44% | HC Wainwright & Co. | Ed Arce | → $82 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2023 | Buy Now | 115.92% | Credit Suisse | Tiago Fauth | → $96 | Assumes | → Outperform | Get Alert |
| 06/07/2023 | Buy Now | 199.15% | Citigroup | Yigal Nochomovitz | $130 → $133 | Maintains | Buy | Get Alert |
| 06/06/2023 | Buy Now | 79.94% | Evercore ISI Group | Liisa Bayko | $60 → $80 | Upgrade | In-Line → Outperform | Get Alert |
| 06/06/2023 | Buy Now | 14.71% | Wedbush | Laura Chico | $48 → $51 | Maintains | Neutral | Get Alert |
| 05/08/2023 | Buy Now | 7.96% | Wedbush | Laura Chico | $47 → $48 | Maintains | Neutral | Get Alert |
| 05/05/2023 | Buy Now | 192.4% | Citigroup | Yigal Nochomovitz | $130 → $130 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | 115.92% | Credit Suisse | Tiago Fauth | → $96 | Reiterates | → Outperform | Get Alert |
| 04/26/2023 | Buy Now | 156.41% | Cantor Fitzgerald | Kristen Kluska | → $114 | Initiates | → Overweight | Get Alert |
| 03/18/2023 | Buy Now | 192.4% | Citigroup | Yigal Nochomovitz | $135 → $130 | Maintains | Buy | Get Alert |
| 02/17/2023 | Buy Now | 115.92% | Credit Suisse | Tiago Fauth | → $96 | Reiterates | → Outperform | Get Alert |
| 02/17/2023 | Buy Now | 28.21% | Baird | Joel Beatty | $50 → $57 | Maintains | Outperform | Get Alert |
| 02/03/2023 | Buy Now | 113.68% | Morgan Stanley | Jeffrey Hung | $100 → $95 | Maintains | Overweight | Get Alert |
| 01/18/2023 | Buy Now | 102.43% | Canaccord Genuity | Whitney Ijem | → $90 | Assumes | → Buy | Get Alert |
| 01/09/2023 | Buy Now | 203.64% | Citigroup | Yigal Nochomovitz | $138 → $135 | Maintains | Buy | Get Alert |
| 12/30/2022 | Buy Now | 84.44% | HC Wainwright & Co. | Ed Arce | → $82 | Assumes | → Buy | Get Alert |
| 11/04/2022 | Buy Now | 23.71% | Goldman Sachs | Salveen Richter | $74 → $55 | Maintains | Neutral | Get Alert |
| 11/03/2022 | Buy Now | 210.39% | Citigroup | Yigal Nochomovitz | $142 → $138 | Maintains | Buy | Get Alert |
| 11/03/2022 | Buy Now | 124.92% | Morgan Stanley | Jeffrey Hung | $109 → $100 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | 142.91% | SVB Leerink | Joseph Schwartz | $115 → $108 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | 115.92% | Credit Suisse | Tiago Fauth | $105 → $96 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | 12.46% | Baird | Joel Beatty | $63 → $50 | Upgrade | Neutral → Outperform | Get Alert |
| 10/13/2022 | Buy Now | 12.46% | Guggenheim | Debjit Chattopadhyay | → $50 | Upgrade | Neutral → Buy | Get Alert |
| 08/02/2022 | Buy Now | 219.39% | Citigroup | Yigal Nochomovitz | $146 → $142 | Maintains | Buy | Get Alert |
| 08/01/2022 | Buy Now | 34.95% | Evercore ISI Group | Liisa Bayko | $95 → $60 | Downgrade | Outperform → In-Line | Get Alert |
| 07/29/2022 | Buy Now | 192.4% | Piper Sandler | Christopher Raymond | $135 → $130 | Maintains | Overweight | Get Alert |
| 07/01/2022 | Buy Now | 219.39% | Stifel | Dae Gon Ha | $176 → $142 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | 127.17% | Goldman Sachs | — | $139 → $101 | Maintains | Neutral | Get Alert |
| 05/19/2022 | Buy Now | 203.64% | Piper Sandler | Christopher Raymond | $170 → $135 | Maintains | Overweight | Get Alert |
| 05/10/2022 | Buy Now | 228.39% | Citigroup | Yigal Nochomovitz | $150 → $146 | Maintains | Buy | Get Alert |
| 05/06/2022 | Buy Now | 145.16% | Morgan Stanley | Jeffrey Hung | $118 → $109 | Maintains | Overweight | Get Alert |
| 05/06/2022 | Buy Now | 158.66% | SVB Leerink | Joseph Schwartz | $178 → $115 | Maintains | Outperform | Get Alert |
| 03/16/2022 | Buy Now | 136.17% | Credit Suisse | Martin Auster | $99 → $105 | Upgrade | Neutral → Outperform | Get Alert |
| 02/11/2022 | Buy Now | 165.41% | Morgan Stanley | Jeffrey Hung | $120 → $118 | Maintains | Overweight | Get Alert |
| 02/11/2022 | Buy Now | 196.9% | JP Morgan | Cory Kasimov | → $132 | Upgrade | Neutral → Overweight | Get Alert |
| 02/01/2022 | Buy Now | 169.91% | Morgan Stanley | Matthew Harrison | $156 → $120 | Maintains | Overweight | Get Alert |
| 09/30/2021 | Buy Now | 138.42% | HC Wainwright & Co. | Edwin Zhang | — | Initiates | → Buy | Get Alert |
| 08/19/2021 | Buy Now | 64.19% | UBS | Esther Rajavelu | — | Initiates | → Sell | Get Alert |
| 08/03/2021 | Buy Now | 104.68% | Wedbush | Laura Chico | — | Maintains | Neutral | Get Alert |
| 08/03/2021 | Buy Now | 217.14% | Barclays | Gena Wang | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Ultragenyx Pharmaceutical (RARE) stock?
The latest price target for Ultragenyx Pharmaceutical (NASDAQ:RARE) was reported by Cantor Fitzgerald on July 22, 2024. The analyst firm set a price target for $115.00 expecting RARE to rise to within 12 months (a possible 158.66% upside). 33 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ultragenyx Pharmaceutical (RARE)?
The latest analyst rating for Ultragenyx Pharmaceutical (NASDAQ:RARE) was provided by Cantor Fitzgerald, and Ultragenyx Pharmaceutical reiterated their overweight rating.
When was the last upgrade for Ultragenyx Pharmaceutical (RARE)?
The last upgrade for Ultragenyx Pharmaceutical Inc happened on June 6, 2024 when Goldman Sachs raised their price target to $67. Goldman Sachs previously had a neutral for Ultragenyx Pharmaceutical Inc.
When was the last downgrade for Ultragenyx Pharmaceutical (RARE)?
The last downgrade for Ultragenyx Pharmaceutical Inc happened on August 1, 2022 when Evercore ISI Group changed their price target from $95 to $60 for Ultragenyx Pharmaceutical Inc.
When is the next analyst rating going to be posted or updated for Ultragenyx Pharmaceutical (RARE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ultragenyx Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ultragenyx Pharmaceutical was filed on July 22, 2024 so you should expect the next rating to be made available sometime around July 22, 2025.
Is the Analyst Rating Ultragenyx Pharmaceutical (RARE) correct?
While ratings are subjective and will change, the latest Ultragenyx Pharmaceutical (RARE) rating was a reiterated with a price target of $115.00 to $115.00. The current price Ultragenyx Pharmaceutical (RARE) is trading at is $44.46, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.